知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

59 records (took 0.029 seconds)

    STABLE AST-3424 INJECTION PREPARATION AND PREPARATION METHOD
    16.
    发明公开
    STABLE AST-3424 INJECTION PREPARATION AND PREPARATION METHOD 审中-公开

    公开(公告)号：US20230181606A1

    公开(公告)日：2023-06-15

    申请号：US17626962

    申请日：2020-07-14

    Applicant: OBI PHARMA, INC

    Inventor： Jianxin Duan

    IPC: A61K31/675 ,  A61K9/08 ,  A61K47/10 ,  A61K47/02 ,  A61J1/14 ,  A61J1/06

    CPC classification number: A61K31/675 ,  A61K9/08 ,  A61K47/10 ,  A61K47/02 ,  A61J1/1468 ,  A61J1/065

    Abstract: A stable AST-3424 injection preparation, being a solution containing 0.1-200 mg/ml or 1-200 mg/ml of AST-3424 active pharmaceutical ingredient. A solvent in the solution contains a C2-C8 monohydric alcohol. The preparation method comprises the following steps: subjecting the AST-3424 active pharmaceutical ingredient and a partial prescription volume of ethanol to a first dissolution and formulation; adding a prescription volume of propylene glycol for a second dissolution and formulation; and then adding the remaining prescription volume of ethanol for mixing and dissolving to obtain a solution containing 1-200 mg/ml of AST-3424 active pharmaceutical ingredient. Provided is an AST-3424 injection for injection, wherein the solvent is water, a glucose solution, ethanol, or propylene glycol, the solutes consist of the AST-3424 active pharmaceutical ingredient, an isotonic regulator, and a pH regulator. The concentration of the AST-3424 active pharmaceutical ingredient of the injection is 0.001-1.000 mg/ml, the pH of the injection is 6.8-10.5, and the solution is an isotonic solution.

    Glycosynthase variants for glycoprotein engineering and methods of use
    18.
    发明授权
    Glycosynthase variants for glycoprotein engineering and methods of use 有权

    公开(公告)号：US11203645B2

    公开(公告)日：2021-12-21

    申请号：US16454750

    申请日：2019-06-27

    Applicant: OBI PHARMA, INC.

    Inventor： Cheng-Der Tony Yu ,  Yih Huang Hsieh ,  Yin-Cheng Hsieh ,  Teng-Yi Huang ,  Yi-Chien Tsai ,  Nan-Hsuan Wang ,  Pu-Ling Hu

    IPC: C07K16/30 ,  C07K16/32 ,  C12N15/85 ,  G01N30/02 ,  G01N30/38

    Abstract: The present disclosure relates to novel glycosynthase enzymes for glycoprotein engineering and/or homogeneous antibody remodeling. The enzyme variants, termed EndoSd-D232M and EndoSz-D234M, contain the glycan conjugation and/or modification activity at the conserved N297 glycosylation site of Fc region of an exemplary antibody. It has been demonstrated that the glycosynthase activities of EndoSd-D232M and EndoSz-D234M can be applied to various mAbs targeting different receptors, including, but not limited to, Globo H, SSEA-4, SSEA-3 series of receptors (OBI-888; Globo H ganglioside), Herceptin (Her 2 receptor), Perj eta (Her 2 receptor) and Vectibix (EGFR receptor). It has been found that both mAb-GlcNAc and mAb-GlucNAc(F) were suitable substrates for both EndoSd-D232M and EndoSz-D234M. The ADCC assay of related products, OBI-888-G2S2 and Herceptin-G2S2, showed that the remodeled homogeneous antibody, mAb-G2S2, has an increased relative activity ranging from 3 to 26 folds.

    Antibodies, pharmaceutical compositions and methods
    19.
    发明授权
    Antibodies, pharmaceutical compositions and methods 有权

    公开(公告)号：US11041017B2

    公开(公告)日：2021-06-22

    申请号：US15473267

    申请日：2017-03-29

    Applicant: OBI Pharma, Inc.

    Inventor： Cheng-Der Tony Yu ,  Jiann-Shiun Lai ,  I-Ju Chen ,  Chiu-Chun Lin

    IPC: C07K16/00 ,  A61K39/395 ,  C07K16/18 ,  G01N33/92 ,  C07K16/44 ,  G01N33/574 ,  A61P35/00 ,  A61K39/00

    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.

    Antibodies, pharmaceutical compositions and methods
    20.
    发明授权
    Antibodies, pharmaceutical compositions and methods 有权

    公开(公告)号：US10980894B2

    公开(公告)日：2021-04-20

    申请号：US15996192

    申请日：2018-06-01

    Applicant: OBI Pharma, Inc.

    Inventor： Cheng-Der Tony Yu ,  Jiann-Shiun Lai ,  I-Ju Chen ,  Chiu-Chun Lin

    IPC: C07K16/00 ,  A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K31/4025 ,  A61K39/395 ,  C07K16/18 ,  C07K16/30 ,  A61K39/00

    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.

Patent Agency Ranking